IXA is a network, servicedesk and liaison, all in one.
We offer researchers the expertise of grant advisers, business developers and legal experts to help determine a valorisation/ impact strategy. We assist in setting up collaborations with third parties and/or starting new ventures, while managing intellectual property and other legal and financial support. For researchers to develop their skills on valorisation and entrepreneurship, IXA organises workshops, courses and masterclasses on a regular basis. Go to For researchers for more information or have a look at our Workshops & Events page.
For companies, non-profits, governments, health care and educational institutions, etc., we provide a gateway to research expertise, high-tech facilities and research infrastructure, contract research, collaboration and investment opportunities. Go to For companies/non-profits to find out more.
Next to offering a wide range of services, we closely cooperate with other parties within the Amsterdam innovation landscape. When opportunities arise, IXA takes the lead in developing programs and activities to further stimulate economic activity and entrepreneurship in research and education.
Panel B.V., a spin-off from the University of Amsterdam, has received a loan from the Innovatiefonds Noord-Holland. This loan will enable Panel to continue building its innovative tool for inclusive participation processes. The unique method was designed by sociologists Gerben Moerman and Christiaan Bröer of the UvA Faculty of Social and Behavioural Sciences. The method […]
NewsPhotosynthetic & Veridis, two VU start-ups, are part of the Pole Position Programme #4 by Techleap. Through the programme, like-minded industry experts who will guide the founders of Photosynthetic & Veridis on their journey towards becoming global leaders and take Pole Position. Techleap is a government funded organization to connect and empower startups to grow and sustain a productive tech community.
NewsPhlox, a private biotechnology spin-off from Amsterdam UMC and specializing in developing innovative RNA-therapeutics for rare genetic cardiomyopathies, has secured additional seed funding to advance Phlox’s lead program aimed at rare genetic laminopathies.
News